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Abstract
Background: Gonorrhoea is a common sexually transmitted infection which causes genital pain and discomfort;
in women it can also lead to pelvic inflammatory disease and infertility, and in men to epididymo-orchitis. Current
treatment is with ceftriaxone, but there is increasing evidence of antimicrobial resistance which is reducing its
effectiveness against gonorrhoea. A small, but increasing, number of patients have already been found to have
highly resistant strains of gonorrhoea which has been associated with clinical failure. This trial aims to determine
whether gentamicin is not clinically worse than ceftriaxone in the treatment of gonorrhoea.
Methods/design: This is a blinded, two-arm, multicentre, noninferiority randomised trial. Patients are eligible if
they are aged 16–70 years with a diagnosis of genital, pharyngeal and/or rectal gonorrhoea. Exclusion criteria are:
known concurrent sexually transmitted infection(s) (excluding chlamydia); bacterial vaginosis and/or Trichomonas
vaginalis infection; contraindications or an allergy to gentamicin, ceftriaxone, azithromycin or lidocaine; pregnancy
or breastfeeding; complicated gonorrhoeal infection; weight under 40 kg; use of ceftriaxone, gentamicin or
azithromycin within the preceding 28 days. Randomisation is to receive a single intramuscular injection of either
gentamicin or ceftriaxone, all participants receive 1 g oral azithromycin as standard treatment. The estimated
sample size is 720 participants (noninferiority limit 5%).
The primary outcome is clearance of Neisseria gonorrhoeae at all infected sites by a negative Nucleic Acid
Amplification Test, 2 weeks post treatment. Secondary outcomes include clinical resolution of symptoms,
frequency of adverse events, tolerability of therapy, relationship between clinical effectiveness and antibiotic
minimum inhibitory concentration for N. gonorrhoeae, and cost-effectiveness.
Discussion: The options for future treatment of gonorrhoea are limited. Results from this randomised trial will
demonstrate whether gentamicin is not clinically worse than ceftriaxone for the treatment of gonorrhoea. This
will inform clinical practice and policy for the treatment of gonorrhoea when current therapy with cephalosporins
is no longer effective, or is contraindicated.
Trial registration: International Standard Randomised Controlled Trial Number – ISRCTN51783227, Registered on
18 September 2014. Current protocol version 2.0 17 June 2015.
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Background
Gonorrhoea is the second most common bacterial sexu-
ally transmitted infection (STI) in the UK, with 34,958
infections reported in 2014 [1]. A disproportionate bur-
den of infection is seen in young adults and minority
ethnic groups (35% of infections). The highest rates of
infection are in large urban areas, and infection is con-
centrated in core high-risk groups such as men who
have sex with men (MSM), black and minority ethnic
(BME) groups, and those reporting multiple sexual part-
ners. There has recently been a significant rise in rectal
gonorrhoea in MSM thought to reflect an increase in
unsafe sexual behaviour [2].
Gonorrhoea leads to local inflammation causing geni-
tal pain and discomfort, and the localised immune acti-
vation also facilitates the acquisition and transmission of
HIV. In women, infection can spread to the fallopian
tubes and ovaries causing pelvic inflammatory disease
with resultant tubal scarring, infertility, chronic pelvic
pain and an increased risk of ectopic pregnancy. In men,
gonorrhoea can lead to epididymo-orchitis and, in men
who have sex with men, gonococcal proctitis can lead to
abscess and fistula formation. Pharyngeal infection,
whilst usually asymptomatic, is an important reservoir of
onward transmission in both women and MSM. It is also
harder to treat with antibiotics [3] and can persist even
when sensitivity testing suggests that it should be
susceptible [3]. It is, therefore, important to find out
whether treatment is effective for infection at all ana-
tomical sites.
Antibiotic treatment and resistance
Neisseria gonorrhoeae readily develops resistance to anti-
biotic regimens. There are now high levels of resistance
against penicillins, sulphonamides, tetracyclines and
quinolones, all of which are no longer recommended for
use. A real possibility of multidrug-resistant gonorrhoea
and the lack of treatment options has recently been
highlighted [4]. Guidance from the British Association
for Sexual Health and HIV (BASHH) is to treat with
ceftriaxone (given with adjunctive azithromycin) and this
currently cures over 95% of patients [2]. Recent surveil-
lance data show a reduction in sensitivity to ceftriaxone
with an upward drift in the minimum inhibitory concen-
tration (MIC) (13% with MIC over 0.03 mg/l in 2010 cf.
1% in 2007), i.e. the proportion of cases which remain
highly sensitive to ceftriaxone has decreased over time
[5]. Sporadic clinical failure of cephalosporins has been
reported from Japan, Sweden, Spain and France [6–10].
The same reduction in antibiotic sensitivity was followed
by widespread clinical failure within a few years for other
antimicrobials (penicillin, tetracyclines and quinolones)
used to treat gonorrhoea. More recently an outbreak of
azithromycin-resistant gonorrhoea has been reported in
England further highlighting the need to identify other
effective treatment regimens [11]. Despite this recent
outbreak azithromycin resistance remains uncommon in
England and levels of azithromycin resistance have not
increased over the past 18 months since the outbreak
was first identified. Current national and international
treatment guidelines continue to recommend dual anti-
biotic therapy, including azithromycin, for the treatment
of gonorrhoea. The ongoing use of azithromycin will be
monitored during the trial to ensure that its use remains
appropriate.
Alternative treatment
If cephalosporins become ineffective the options for
treating gonorrhoea are currently limited. With the ex-
ception of gentamicin, alternative agents have either not
been assessed in vivo (such as ertapenem, solithromycin)
[12–15], are reserved for specific infections (e.g. rifampi-
cin for tuberculosis) [16] or have the potential to rapidly
develop resistance (e.g. spectinomycin) [17].
Two recent systematic reviews on gentamicin mono-
therapy reported cure rates for gentamicin of 62–98% in
patients with gonorrhoea, but available studies were gen-
erally small and of low quality with a significant risk of
bias and random error [18, 19]. No adverse events (AEs)
were reported in these studies. A more recent two-arm
prospective study evaluated single-dose gentamicin com-
bined with 2 g oral azithromycin with a reported cure
rate of 100% [20]. Limited data are available on the effi-
cacy of gentamicin when treating gonorrhoea in the
pharynx or rectum, although antibiotics are sometimes
less effective at these sites.
Why a trial is needed now
As the susceptibility of N. gonorrhoeae to currently rec-
ommended antibiotics decreases and multidrug-resistant
strains become more common, it is important to dem-
onstrate the efficacy and safety of alternative treatment
regimens in patients with gonorrhoea. Gentamicin is a
cheap and widely available antibiotic. It has been associ-
ated with renal and vestibulo-cochlear toxicity, which is
partially dose-related [21], and the use of a single one-
off dose appears to be well-tolerated [22]. In vitro micro-
bial sensitivity data [23] support the use of gentamicin
but there is need for clinical trial data to assess its effi-
cacy and safety, particularly in pharyngeal and rectal
infections.
Our hypothesis is that gentamicin is not clinically
worse than ceftriaxone in the treatment of gonorrhoea.
The aim is to test this hypothesis in a randomised trial
by comparing microbiological clearance of N. gonor-
rhoeae following treatment with gentamicin or with
ceftriaxone.
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Methods/design
This is a blinded, two-arm, multicentre, noninferiority,
randomised trial comparing the clinical effectiveness and
safety of gentamicin and ceftriaxone in the treatment of
gonorrhoea.
Participants
Patients are eligible for the trial if they are aged 16–70
years and have received a positive diagnosis in the last
4 weeks of uncomplicated, untreated (not received any
antibiotic in the previous 28 days which could have
treated gonorrhoea, either partially or completely) geni-
tal, pharyngeal and/or rectal gonorrhoea. Diagnosis must
be based on a positive gram-stained smear on micros-
copy, or a positive Nucleic Acid Amplification Test
(NAAT). Current treatment guidelines do not differenti-
ate their recommendations by sex of patient and there is
no evidence from previous studies that treatment re-
sponse differs between men and women, thus both male
and female patients are eligible to take part in the trial.
Exclusion criteria are known concurrent bacterial STI
(apart from chlamydia); known bacterial vaginosis and/or
Trichomonas vaginalis infection; known contraindications
or an allergy to gentamicin, ceftriaxone, azithromycin or
lidocaine; patients with a current clinical diagnosis of
complicated gonorrhoeal infections, for example pelvic
inflammatory disease, epididymo-orchitis; patients who
weigh less than 40 kg; patients who are receiving or have
received ceftriaxone, gentamicin or azithromycin within
the preceding 28 days. Pregnant and breastfeeding women
are also excluded. Patients are only eligible to participate
in the trial once.
Patients are recruited from 13 outpatient sexual health
clinics in England, all of which offer direct self-referral
with both a walk-in service and prebookable appoint-
ments. Clinics are situated in urban locations and care is
provided by specialist medical and nursing staff follow-
ing national management guidelines [24]. Some clinics
seeing a high proportion of MSM were purposely chosen
to maximise the number individuals with pharyngeal
and rectal infections included in the trial.
Interventions
Participants are randomised to receive either gentamicin
240 mg (intervention) or ceftriaxone 500 mg (current
standard treatment) and treatment is administered after
obtaining consent during the same clinic visit.
Both treatments are administered from routine clinic
stock as a single intramuscular injection. Ceftriaxone
(500 mg) is a powder formulation and is dissolved in 1%
lidocaine in accordance with the Summary of Product
Characteristics (SmPC) and administered as a single 2-
ml intramuscular injection. Gentamicin (240 mg) is
made up from 3 × 2-ml (80-mg) vials in accordance with
the SmPC and administered as a single 6-ml intramus-
cular injection. In addition, all participants receive a sin-
gle oral dose of 1 g azithromycin, which is currently
given as standard treatment alongside ceftriaxone.
Previous trials have most commonly used a 240-mg
dose of gentamicin and the use of different doses has
not demonstrated a significant dose-response effect
across studies. In vitro susceptibility testing also suggests
that isolates remain sensitive to gentamicin [23, 25]. The
dose of ceftriaxone was chosen to be consistent with
current UK gonorrhoea treatment guidelines [24].
Outcomes measures
The primary outcome measure is clearance of N. gonor-
rhoeae at all infected sites confirmed by a negative
NAAT 2 weeks post treatment (as recommended by the
British Association for Sexual Health and HIV).
The NAAT is an automated laboratory test and, there-
fore, it is not subject to bias through knowledge of treat-
ment allocation. The method of NAAT (e.g. Aptima
Combo (AC), Becton Dickinson (BD), Roche Cobas) per-
formed varies between sexual health centres; therefore,
in order to ensure consistency and standardisation in
diagnostic and follow-up tests performed by local la-
boratories, additional samples are taken from partici-
pants recruited at centres where the AC NAAT method is
not used by the local laboratory. Testing of these samples
by AC NAAT is performed by a central laboratory (the
Sexually Transmitted Bacteria Reference Unit (STBRU)
within Public Health England). The results from the AC
NAAT will be used to assess clearance for the primary
endpoint.
Secondary outcomes are:
 Clinical resolution of symptoms
 frequency of nausea/vomiting, hearing loss, dizziness
and rash
 Frequency of any other AEs reported by participants
 tolerability of injection as assessed by the participant
on a Visual Analogue Scale (VAS)
 Cost-effectiveness
The relationship between clearance of gonorrhoea and
in vitro measurement of antibiotic MIC to inhibit N.
gonorrhoeae growth will be assessed.
Effectiveness, tolerability and safety are assessed at a
follow-up visit 2 weeks post treatment.
Sample size
Based on a cure rate of 96% for the ceftriaxone regimen,
which is consistent with previous trials, a total sample
size of 646 for analysis (323 in each group) will achieve a
90% power to detect noninferiority with lower confi-
dence interval for an absolute risk difference of 5%. The
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one-sided significance level is 0.025. To allow for a loss
to follow-up rate of up to 10%, the trial will recruit a
total of 720 participants.
Consent
Patients with a provisional (indicated by a positive gram
stain of genital secretions on microscopy) or confirmed
(indicated by a positive NAAT) diagnosis of gonorrhoea
are screened for the trial and approached by a member
of the site research team to determine whether they are
interested in participating. They are provided with a
Patient Information Sheet and given a verbal explanation
of the trial with the opportunity to ask any questions
and have these addressed. In addition, trial posters are
on display in relevant areas of the clinic. These help to
introduce the trial and, if patients are interested, they
can ask clinic staff for additional details.
To avoid delaying treatment for a transmissible infection
with serious sequelae, patients with either a provisional
(on microscopy) or confirmed diagnosis (on NAAT) of
untreated gonorrhoea are invited to participate and pro-
vide written consent at the same clinic visit.
Randomisation
After providing consent, participants are registered in
the trial using a web-based registration and randomisa-
tion system. Once eligibility is confirmed, participants
are randomised to either gentamicin or ceftriaxone by a
member of the research team. Staff who perform ran-
domisation have no role in administering trial treat-
ments and remain blinded to the treatment allocation,
thereby minimising risk of selection bias through predic-
tion of the allocation sequence.
Randomisation is based on a computer-generated
pseudo-random code using permuted blocks of ran-
domly varying size, created by the Nottingham Clinical
Trials Unit (NCTU) in accordance with their Standard
Operating Procedure and held on a secure server.
Randomisation is in a 1:1 ratio, stratified by recruiting
centre.
The web-based system generates a blinded prescrip-
tion for G-TOG trial treatment which must be signed by
the prescribing doctor. Site staff record only ‘G-TOG
study drug’ in the participant’s medical notes. The signed
prescription is passed to a nurse who administers the al-
located treatment.
Blinding of the assessment of outcome
Nurses administering trial treatments are required to
know each participant’s allocation since they must
formulate the drug into a single injection. Details of the
nurses administering treatment at each centre are
obtained during the trial set-up stage and access to the
online randomisation allocation is granted according to
the role. All other staff at the recruiting centres remain
blinded to treatment allocation.
Preparation and administration of trial treatments is
undertaken in a separate area away from the blinded
research team and the participant. In addition, nurses
administering treatment are given guidance to provide
standardised information to participants at the time of
injection, which is the same regardless of treatment allo-
cation, to prevent inadvertent unblinding. This two-step
approach maintains blinding for members of the
research team who are subsequently involved in the as-
sessment of the participant.
To ensure that assessment of outcome is not influ-
enced by knowledge of the allocated treatment, nurses
administering trial treatments are not permitted any role
in the collection of outcome data to reduce risk of ascer-
tainment bias.
Baseline visit
During the baseline visit, demographic information is
collected together with details of the participant’s sexual
history and their symptoms.
For symptomatic participants, the baseline visit usually
takes place on the same day as diagnosis based on the
appearances of gram-stained genital discharge on
microscopy. Asymptomatic participants are recalled to
clinic for treatment following a positive diagnosis; once
they have given consent to participate in the trial this
second visit (the first following diagnosis) is considered
as the baseline visit.
Each participant has swabs taken for NAAT and cul-
ture testing to determine the sites of infection. A full
sampling profile is required according to the partici-
pant’s gender and sexual orientation to reflect potential
sites of exposure. This will allow the efficacy of treat-
ment to be assessed at each infected site. Where swabs
are not part of routine clinical care or have not been
taken already during the baseline clinic visit (e.g. symp-
tomatic participants where only swabs have been taken
for routine care on the same day prior to consent), add-
itional swabs are taken to complete the full sampling
profile as defined in Table 1.
All samples collected are sent to local site laboratories
for analysis and results are reported back to the clinic in
Table 1 Sampling schedule for trial participants
Sex/reported sexual orientation Genital sample Pharynx Rectum
Women ✔a ✔c ✔c
Heterosexual men ✔b X X
Men who have sex with men ✔b ✔c ✔c
aCulture sample from cervix, Nucleic Acid Amplification Test (NAAT) sample
from vagina or cervix
bCulture sample from urethra, NAAT sample from urine or urethra
cCulture sample plus NAAT sample
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the usual manner. The results from the baseline visit in-
form subsequent testing of previously infected sites at
the follow-up visit.
In centres where AC NAAT is not used for local test-
ing, an additional set of swabs is taken for AC NAAT by
the central laboratory. The results of any tests performed
by the central laboratory are not provided back to the
clinic and are reported in batches to the NCTU.
Management of the participant is based only on the re-
sults of local testing.
An additional blood sample is taken for measurement
of the pretreatment immune response to gonococcal
infection.
Follow-up of participants
Participants are asked to return to clinic 2 weeks post
treatment (which is also 2 weeks post randomisation) for
a follow-up visit. Participants are reminded of their ap-
pointments using the individual clinic’s existing recall
procedures such as by short messaging service (SMS)
messaging and telephone reminders. During the follow-
up visit swabs from previously infected sites are taken
for NAAT and culture to assess clearance of N. gonor-
rhoeae. A blood sample is taken to measure the post-
treatment immune response. Each participant remains
in the trial until this follow-up visit is completed. Partici-
pants are considered lost to follow-up if they have not
returned for their follow-up appointment within 60 days
of the baseline visit; this time point was chosen to allow
younger participants, who are often working or have
childcare commitments, enough flexibility to return to
clinic, whilst not leaving it so long that the risk of
reinfection was increased. The recruitment flow diagram
is shown in Fig. 1.
If follow-up test results show that the participant has
gonorrhoea, they are offered further investigation and
treatment according to local clinic guidelines. This is not
considered as part of the trial.
Clinical resolution of symptoms
Participants are asked about their symptoms at the base-
line visit, and they may also have a clinical examination
if clinically indicated. Resolution of symptoms is assessed
at the follow-up visit 2 weeks later.
Frequency of adverse events and tolerability of therapy
Following the administration of the intramuscular treat-
ment (baseline visit), participants are asked to complete
a VAS to assess any pain associated with their injection.
Participants are then asked to complete a second VAS at
the follow-up visit to again assess their perception of
injection discomfort experienced at baseline.
Adverse events and serious AEs from baseline to the
end of the follow-up visit are collected. The known side
effects of both gentamicin and ceftriaxone (nausea/
vomiting, hearing loss, dizziness and rash) are assessed
by direct questioning during the follow-up visit by a
member of the research team blind to the allocated
treatment group. Ototoxicity and nephrotoxicity are the
most common side effects associated with gentamicin
therapy. Both effects are related to renal impairment and
their frequency following a single dose of gentamicin is
not known. Other AEs are collected by direct question-
ing of the participant by a member of the research team
at site; participants are asked about any additional new
symptoms or complaints (i.e. those not existing before
administration of the treatment). In addition, all partici-
pants have a blood sample taken at the baseline and
follow-up visit to assess changes in creatinine level.
Cost-effectiveness
Participants are asked questions during their follow-up
visit about any additional health resource (e.g. GP or
other clinic visit) use since the baseline visit. The eco-
nomic analysis will compare the costs associated with
the current standard treatment, ceftriaxone, with those
of the proposed alternative treatment, gentamicin, in the
treatment of gonorrhoea. Given that the primary object-
ive of the trial is to determine noninferiority of gentami-
cin compared to ceftriaxone, the economic analysis will
focus on establishing whether the use of gentamicin ra-
ther than ceftriaxone is cost-neutral in the treatment of
gonorrhoea. This will involve the examination of costs
and resource use to determine whether there are any
differences between the two treatments.
Data management and trial monitoring
Data are entered into a trial-specific database developed
and maintained by the Nottingham Clinical Trials Unit
(NCTU). Access to the database is restricted and secure.
All trial data are anonymised by use of unique partici-
pant trial numbers. Data quality is checked using criteria
for out-of-range and consistency, and checks for con-
flicting data within and between Data Collections Forms.
Missing data and data queries are referred promptly
back to the recruiting site for clarification.
Trial monitoring is by central statistical monitoring
combined with site visits. Central statistical monitoring
is used to assess compliance with protocol, monitor pat-
terns of recruitment at sites, reasons for nonrecruitment
and tracking of participant samples. Each site will have
at least one monitoring visit. The timing of this visit is
influenced by recruitment, data quality and compliance
with the protocol and trial procedures.
The trial is conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki, 2013, with relevant regulations and with MRC
Guidelines for Good Clinical Practice in Clinical Trials
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Fig. 1 Trial flow diagram
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which is based on International Conference on Harmon-
isation (ICH) guidelines for Good Clinical Practice
(GCP) (CPMP/ICH/135/95) July 1996.
Statistical analyses
Demographic and clinical measures will be compared
between the randomised arms at baseline using appro-
priate descriptive statistics for continuous and categor-
ical variables.
The primary approach to between-group comparative
analyses will be by intention-to-treat without imputation
of missing outcome data. Sensitivity analyses will be
conducted to investigate the impact of missing primary
outcome data, using simple and multiple imputation.
Due to both interventions being single-dose adminis-
tered immediately following randomisation, nonadher-
ence with treatment allocation is expected to be low.
Therefore, additional sensitivity analyses that aim to esti-
mate treatment effect amongst those who have adhered
with allocation are not expected to be required.
The evaluation of the primary clinical outcome variable
will be performed using a general linear model for binary
outcome adjusted by clinic site. The primary efficacy par-
ameter comparing gentamicin with ceftriaxone will be the
difference in the proportion of participants clear of infec-
tion at 2 weeks follow-up along with the 95% confidence
interval. Gentamicin will be regarded as noninferior if the
lower 95% confidence limit for the risk difference in con-
firmed clearance is −5 percentage points or greater.
Secondary outcomes will be similarly analysed using
appropriate regression models dependent on data type,
adjusted for clinic site and baseline value of the outcome
variable if collected. These analyses will be considered
supportive to the primary analyses.
To explore treatment efficacy by site of infection, for
each of the three infection sites, we will separately esti-
mate clearance by treatment arm along with 95% confi-
dence intervals, rather than formally fit an interaction
term for the seven different possible combinations of
infection site in the regression model. Any suggestion of
a differential effect according to infected site would re-
quire confirmation in future research.
The relationship between clinical effectiveness and
MIC will be examined visually.
Safety and tolerability analyses will be descriptive. Fre-
quency counts and percentages of the prespecified main
categories of AEs will be presented by treatment arm.
All planned analyses will be described in the Statistical
Analysis Plan which will be finalised prior to database
lock and unblinding of the trial.
Trial management and oversight
Day-to-day management of the trial is the responsibility
of the Trial Management Group (TMG), which meets at
least every 2 months and more often if required. Trial
oversight is by an independent Trial Steering Committee
(TSC). Safety of trial participants is monitored by an
independent Data Monitoring Committee (DMC), which
reports to the TSC. The trial is coordinated by the
NCTU.
Discussion
The G-TOG trial is designed to be a pragmatic trial
which aims to reflect routine NHS clinical practice and
thus trial procedures, as far as possible, mirror routine
clinical practice. Careful consideration and training was
given during the set-up stage of the trial to ensure that
maintenance of the blind was both feasible and practic-
able at each participating site without causing any
additional burden of work for site staff. An initial assess-
ment of current practice was conducted to identify any
potential problems at each site in concealing treatment
allocation from both participant and the blinded site re-
search team. This included suitability of the areas where
treatment is administered to ensure adequate privacy
from any blinded members of the research team. Nurses
administering treatment are trained on the importance
of provision of consistent information to all participants,
regardless of treatment allocation. Treatment adminis-
tered to trial participants is obtained from standard clinic
stock, thus it was also essential to consider whether access
to the storage areas for drugs could also result in inadvert-
ent unblinding.
A key challenge for site staff in recruiting patients into
the trial is the need to ensure adequate availability of
GCP and trial-trained staff since the trial demands both
a blinded research nurse/physician and an unblinded
nurse administering treatment to perform separate roles
during the initial clinic visit. This has meant training a
larger number of staff than would ordinarily be required
for a trial of this size.
The trial is designed so that participants, clinicians
and researchers are blinded to treatment allocation.
Whilst the primary end point of the trial is objective and
so not subject to bias from knowledge of treatment
intervention, blinding to allocation is necessary to min-
imise selection bias at recruitment and to ensure that
ascertainment of outcome and assessment of safety is
not biased by knowledge of the administered treatment.
Gentamicin is not currently recommended for use in
the UK to treat gonorrhoea due to a lack of efficacy and
safety data. The results of this trial will assess whether
gentamicin is not clinically worse than ceftriaxone for
the treatment of gonorrhoea, when resistance to
current antibiotics leads to clinical failure. The trial will
generate knowledge about the efficacy of gentamicin in
the treatment of gonorrhoea, both at genital and non-
genital sites, extend our knowledge of the safety of
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single-dose gentamicin therapy and provide data to
correlate laboratory-based sensitivity testing with the
clinical response to treatment (thus helping to calculate
the MIC ‘breakpoints’ which can be used to predict
from laboratory testing whether a patient will respond
to treatment).
It is expected that the results of the trial will inform
future guidelines on the treatment of gonorrhoea, influ-
ence policy recommendations on antimicrobial testing
and surveillance, and assist developing countries in choos-
ing evidence-based affordable gonorrhoea treatment.
Trial status
Recruitment to the G-TOG trial commenced in October
2014 and is expected to continue until the end of
October 2016. So far, 593 patients have been randomised
(as of 11 July 2016). At the time of writing, thirteen sex-
ual health outpatient clinics in England were participat-
ing in the trial.
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